Identification of gain-of-function variants of the human prolactin receptor

Methods in Enzymology

Volumn 484, Issue C, 2010, Pages 329-355

  Goffin, Vincent ^a   Bogorad, Roman L ^a,c   Touraine, Philippe ^a,b  

^a INSERM   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROLACTIN RECEPTOR;

APOPTOSIS; BIOASSAY; BOOK; BREAST TUMOR; CANCER RESISTANCE; CELL CLONE; CELL LINE; CELL POPULATION; CELL PROLIFERATION; CELL STRAIN HEK293; CELL STRAIN MCF 7; CELL SURVIVAL; EXPERIMENTAL MODEL; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LABORATORY TEST; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REPORTER GENE; TRANSIENT TRANSFECTION;

EID: 78049250338     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381298-8.00017-4     Document Type: Chapter

References (30)

1. Bazan F. A novel family of growth factor receptors: A common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and p75 IL-2 receptor β-chain. Biochem. Biophys. Res. Commun. 1989, 164:788-795.
2. Ben Jonathan N., Lapensee C.R., Lapensee E.W. What can we learn from rodents about prolactin in humans?. Endocr. Rev. 2008, 29:1-41.
3. Berlanga J.J., Gualillo O., Buteau H., Applanat M., Kelly P.A., Edery M. Prolactin activates tyrosyl phosphorylation of insulin receptor substrate-1 and phosphatidylinositol-3-OH kinase. J. Biol. Chem. 1997, 272:2050-2052.
4. Bernichtein S., Jeay S., Vaudry R., Kelly P.A., Goffin V. New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity. Endocrine 2003, 20:177-190.
5. Bogorad R.L., Courtillot C., Mestayer C., Bernichtein S., Harutyunyan L., Jomain J.B., Bachelot A., Kuttenn F., Kelly P.A., Goffin V., Touraine P. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc. Natl. Acad. Sci. USA 2008, 105:14533-14538.
6. Bole-Feysot C., Goffin V., Edery M., Binart N., Kelly P.A. Prolactin and its receptor: actions, signal transduction pathways and phenotypes observed in prolactin receptor knockout mice. Endocr. Rev. 1998, 19:225-268.
7. Boutin J.M., Edery M., Shirota M., Jolicoeur C., Lesueur L., Ali S., Gould D., Djiane J., Kelly P.A. Identification of a cDNA encoding a long form of prolactin receptor in human hepatoma and breast cancer cells. Mol. Endocrinol. 1989, 3:1455-1461.
8. Broutin I., Jomain J.B., Tallet E., Van Agthoven J., Raynal B., Hoos S., Kragelund B.B., Kelly P.A., Ducruix A., England P., Goffin V. Crystal structure of an affinity-matured prolactin complexed to its dimerized receptor reveals the topology of hormone binding site 2. J. Biol. Chem. 2010, 285:8422-8433.
9. Canbay E., Degerli N., Gulluoglu B.M., Kaya H., Sen M., Bardakci F. Could prolactin receptor gene polymorphism play a role in pathogenesis of breast carcinoma?. Curr. Med. Res. Opin. 2004, 20:533-540.
10. Clevenger C.V., Furth P.A., Hankinson S.E., Schuler L.A. The role of prolactin in mammary carcinoma. Endocr. Rev. 2003, 24:1-27.
11. Courtillot C., Chakhtoura Z., Bogorad R., Genestie C., Bernichtein S., Badachi Y., Janaud G., Akakpo J.P., Bachelot A., Kuttenn F., Goffin V., Touraine P. Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breast fibroadenomas. J. Clin. Endocrinol. Metab. 2010, 95:271-279.
12. Glasow A., Horn L.C., Taymans S.E., Stratakis C.A., Kelly P.A., Kohler U., Gillespie J., Vonderhaar B.K., Bornstein S.R. Mutational analysis of the PRL receptor gene in human breast tumors with differential PRL receptor protein expression. J. Clin. Endocrinol. Metab. 2001, 86:3826-3832.
13. Goffin V., Bernichtein S., Touraine P., Kelly P.A. Development and potential clinical uses of human prolactin receptor antagonists. Endocr. Rev. 2005, 26:400-422.
14. Goffin V., Shiverick K.T., Kelly P.A., Martial J.A. Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals. Endocr. Rev. 1996, 17:385-410.
15. Horseman N.D., Zhao W., Montecino-Rodriguez E., Tanaka M., Nakashima K., Engle S.J., Smith F., Markoff E., Dorshkind K. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J. 1997, 16:6926-6935.
16. Ibrahim N.M., Marinovic A.C., Price S.R., Young L.G., Frohlich O. Pitfall of an internal control plasmid: Response of Renilla luciferase (pRL-TK) plasmid to dihydrotestosterone and dexamethasone. Biotechniques 2000, 29:782-784.
17. Jeay S., Sonenshein G., Postel-Vinay M.C., Baixeras E. Growth hormone prevents apoptosis through activation of nuclear factor-κB in interleukin-3-dependent Ba/F3 cell line. Mol. Endocrinol. 2000, 14:650-661.
18. Jomain J.B., Tallet E., Broutin I., Hoos S., Van Agthoven J., Ducruix A., Kelly P.A., Kragelund B.B., England P., Goffin V. Structural and thermodynamical bases for the design of pure prolactin receptor antagonists. X-ray structure of Del1-9-G129R-hPRL. J. Biol. Chem. 2007, 282:33118-33131.
19. Kinet S., Bernichtein S., Llovera M., Kelly P.A., Martial J.A., Goffin V. Molecular basis of the interaction between human prolactin and its membrane receptor: A ten year study. Recent Res. Devel. Endocrinol. 2001, 2:1-24.
20. LeBaron M.J., Ahonen T.J., Nevalainen M.T., Rui H. In vivo response-based identification of direct hormone target cell populations using high-density tissue arrays. Endocrinology 2007, 148:989-1008.
21. Lebrun J.J., Ali S., Goffin V., Ullrich A., Kelly P.A. A single phosphotyrosine residue of the prolactin receptor is responsible for activation of gene transcription. Proc. Natl. Acad. Sci. USA 1995, 92:4031-4035.
22. Lee S.A., Haiman C.A., Burtt N.P., Pooler L.C., Cheng I., Kolonel L.N., Pike M.C., Altshuler D., Hirschhorn J.N., Henderson B.E., Stram D.O. A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: The multiethnic cohort. BMC Med Genet. 2007, 8:72.
23. Llovera M., Pichard C., Bernichtein S., Jeay S., Touraine P., Kelly P.A., Goffin V. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene 2000, 19:4695-4705.
24. Molitch M.E. Dopamine resistance of prolactinomas. Pituitary 2003, 6:19-27.
25. Ormandy C.J., Camus A., Barra J., Damotte D., Lucas B.K., Buteau H., Edery M., Brousse N., Babinet C., Binart N., Kelly P.A. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev. 1997, 11:167-178.
26. Riddle O., Bates R.W., Dykshorn S.W. The preparation, identification and assay of prolactin-A hormone of the anterior pituitary. Am. J. Physiol. 1933, 105:191-216.
27. Stricker P., Grueter R. Action du lobe antérieur de l'hypophyse sur la montée laiteuse. C. R. Soc. Biol. 1928, 99:1978-1980.
28. Utama F.E., Tran T.H., Ryder A., LeBaron M.J., Parlow A.F., Rui H. Insensitivity of human prolactin receptors to nonhuman prolactins: Relevance for experimental modeling of prolactin receptor-expressing human cells. Endocrinology 2009, 150:1782-1790.
29. Vaclavicek A., Hemminki K., Bartram C.R., Wagner K., Wappenschmidt B., Meindl A., Schmutzler R.K., Klaes R., Untch M., Burwinkel B., Forsti A. Association of prolactin and its receptor gene regions with familial breast cancer. J. Clin. Endocrinol. Metab. 2006, 91:1513-1519.
30. Welsch C.W., Nagasawa H. Prolactin and murine mammary tumorigenesis: A review. Cancer Res. 1977, 37:951-963.